The first-ever World Pancreatic Cancer Coalition (WPCC) will gather for its inaugural meeting in Orlando, Fla., on May 11, bringing together more than 60 individuals representing 40 pancreatic cancer advocacy groups from around the globe. The Coalition’s goal is to drive transformational change for those affected by pancreatic cancer.
“By standing in unison, we hope to save more lives and create a brighter future for the disease with the lowest survival rate of any major cancer,” said Julie Fleshman, JD, MBA, chair of the WPCC and president and CEO of the Pancreatic Cancer Action Network.
Around the world, pancreatic cancer is the seventh most common cause of cancer-related death in men and women combined.1 Only 2 to 10 percent of those diagnosed globally survive five years.2 read more
Eli Lilly and Company marks 140 years of caring and discovery
Over 14 decades, the organization has contributed more than 100 medicines and significant medical advances, such as the first commercially available insulin, manufacturing and global distribution of the Salk polio vaccine and mental health breakthroughs such as anti-depressant Prozacâ (fluoxetine). Today Lilly continues to progress its most robust pipeline in history with dozens of potential new medicines in mid- to late-stage development for cancer, diabetes, autoimmune disease, pain and Alzheimer’s disease.
“As Lilly celebrates 140 years, we’re keeping the vision of our founder alive – from our dedication in the lab to our impact in the community,” said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer, who began his career at Lilly as a chemist in 1979. “Colonel Eli Lilly started this company to put science to work fighting disease and encouraged his successors to ‘take what you find here and make it better and better.’ That vision pushes us daily to honor Colonel Lilly’s legacy and continue in our quest to discover new medicines to help make life better.” read more
Medivir Announces That Janssen Decided to Start a Phase IIb Study of Combinations of Simeprevir, Odalasvir and AL-335 for the Treatment of Hepatitis C
HUDDINGE, Sweden–(BUSINESS WIRE)–Regulatory News:
Medivir AB (STO:MVIRB) today announces that Janssen Research & Development, LLC., part of the Janssen Pharmaceutical Companies (Janssen), has decided to initiate a phase IIb study to investigate the efficacy, safety and pharmacokinetics of different treatment regimens of AL-335, odalasvir, and simeprevir in treatment-naïve and treatment-experienced patients with chronic Hepatitis C Virus (HCV) genotype 1-6 infection, with and without cirrhosis. Further information about the study can be found at www.clinicaltrials.gov. Study identifier: NCT02765490.
Pradaxa®: First NOAC to be assessed in prospective study in patients with blood clots in the veins or venous sinuses of the brain
INGELHEIM, Germany–(EON: Enhanced Online News)–Boehringer Ingelheim will undertake the first prospective, randomised controlled study of a non-vitamin K antagonist oral anticoagulant (NOAC) in patients with blood clots in the veins or venous sinuses of the brain. RE-SPECT CVT® will investigate the safety and efficacy of dabigatran etexilate (Pradaxa®) compared to warfarin for acute treatment and secondary prevention of cerebral venous thrombosis (CVT). The new study was announced at the 2nd European Stroke Organisation Conference 2016 in Barcelona, Spain.1 read more
Boehringer Ingelheim: Nine out of 10 AF patients are concerned about stroke and many want to be part of OAC treatment decisions, new international survey shows
First-of-its-kind survey investigated knowledge of stroke and perceptions about atrial fibrillation (AF) in over 900 AF patients1,2
- Results show that patients actively seek information about treatments to reduce the risk of stroke associated with AF1,2
- Many patients want to be involved in the decision-making process about which oral anticoagulant (OAC) to take1,2 read more
EISAI RECEIVES APPROVAL FOR NEW INDICATION FOR ANTICANCER AGENT HALAVEN® FOR TREATMENT OF ADVANCED LIPOSARCOMA IN EUROPE
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its European regional headquarters Eisai Europe Ltd. (Location: U.K.) has received from the European Commission approval for anticancer agent Halaven® (eribulin mesylate) for the treatment of adult patients with unresectable liposarcomas who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease. Halaven is the first and only single agent to demonstrate a statistically significant overall survival (OS) benefit in a Phase III trial in patients with advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma). Following approval for use in the treatment of metastatic breast cancer, this marks the second indication for which Halaven has received approval based on an extension of OS. read more
Prenoxad Injection Approved in Five European Countries Opening Way for Pan-European Availability of a Take-home Naloxone Product
Significant Opportunity to Reduce Opioid Overdose Deaths
Prenoxad Injection to be Filed for Regulatory Approval in France in Summer 2016
Martindale Pharma, UK-based international specialty pharmaceutical company, today announced the regulatory approval of Prenoxad Injection in Sweden, Denmark, Ireland, Finland and Estonia following the successful completion of a decentralised procedure (DCP).
Developed by Martindale Pharma, Prenoxad Injection is the world’s first take-home naloxone product, designed for use by non-healthcare professionals to treat opioid overdoses in a community setting. Prenoxad Injection is available in the UK and over 85,000 units or kits have been supplied to people who are at risk of opioid related overdose or to their nominated representative. View the European Drug Report here: http://www.emcdda.europa.eu/attachements.cfm/att_239505_EN_TDAT15001ENN.pdf
Braeburn Pharmaceuticals and Camurus announce positive top line results from Phase 2 opioid challenge study with CAM2038 in subjects with opioid use disorder
PRNewswire/ — Braeburn Pharmaceuticals and Camurus today announce top line results of a multiple-dose, pivotal Phase 2 study assessing the blockade by CAM2038 of subjective opioid effects of multiple randomized hydromorphone challenges in adults with opioid use disorder.
A key objective of medication-assisted treatment for opioid use disorder is to reduce or eliminate the use of illicit opioids. The results from the present Phase 2 study demonstrate that CAM2038 blocks effectively the subjective effects of opioid challenges with hydromorphone, including limiting drug liking. read more
Hall of Fame Quarterback Joe Montana and Amgen Team Up to Launch Breakaway from Heart Disease™ to Make Heart Health a Priority
PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the launch of the Breakaway from Heart Disease™ campaign to help make heart health a priority. Hall of Fame quarterback Joe Montana, the American Heart Association and Schwinn are joining forces with Amgen to urge Americans to learn more about their family history of heart disease and get active through cycling. Montana wants others to take charge of their heart health and make meaningful lifestyle changes – just like his family did. read more
DaVita HealthCare Partners Recognized as Top Workplace by The Denver Post Company celebrates five consecutive years on list
PRNewswire/ — DaVita HealthCare Partners (NYSE: DVA), a leading independent medical group and a leading provider of kidney care services in the United States, today announced that the company was recognized as a 2016 Top Workplace by The Denver Post. This is the fifth consecutive year the company has appeared on the list.
“We selected Denver as our home because we align with the local values of civic engagement and the great quality of life,” said Javier Rodriguez, CEO of DaVita Kidney Care. “We are thrilled with the local team’s passion and energy to make our work environment unique and special.”